Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 13, 2018, Pages E3007-E3016

  Widman, Allie J ^a   McMahon, Lori L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Disinhibition; Excitation inhibition balance; GABAergic transmission; Hippocampal networks; Major depression

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; GLYCINE; KETAMINE; RAPASTINEL; RO 256981; SCOPOLAMINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2B NMDA RECEPTOR; SCOPOLAMINE BROMIDE;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DISINHIBITION; DRUG INHIBITION; DRUG MECHANISM; ELECTROPHYSIOLOGY; HIPPOCAMPAL CA1 REGION; IN VITRO STUDY; LOW DRUG DOSE; MALE; NERVE CELL INHIBITION; NERVE EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SYNAPTIC INHIBITION; SYNAPTIC TRANSMISSION; TIME FACTOR; YOUNG ADULT; ACTION POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSION; DRUG EFFECT; HIPPOCAMPUS; INTERNEURON; METABOLISM; NERVE CELL PLASTICITY; PATHOLOGY; SPRAGUE DAWLEY RAT; SYNAPSE;

ACTION POTENTIALS; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; INTERNEURONS; KETAMINE; MALE; NEURONAL PLASTICITY; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SCOPOLAMINE HYDROBROMIDE; SYNAPSES;

EID: 85044513437     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1718883115     Document Type: Article

References (62)

1. Berman RM, et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
2. Zarate CA, Jr, et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
3. Duman RS (2014) Pathophysiology of depression and innovative treatments: Remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci 16:11-27.
4. Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med 22:238-249.
5. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: Potential therapeutic targets. Science 338:68-72.
6. Gerhard DM, Wohleb ES, Duman RS (2016) Emerging treatment mechanisms for depression: Focus on glutamate and synaptic plasticity. Drug Discov Today 21:454-464.
7. Li N, et al. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
8. Li N, et al. (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69: 754-761.
9. Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS (2014) BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol 18: pyu033.
10. Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27: 11496-11500.
11. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927.
12. Miller OH, Moran JT, Hall BJ (2016) Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition. Neuropharmacology 100:17-26.
13. Miller OH, et al. (2014) GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife 3: e03581.
14. Pozzi L, Pollak Dorocic I, Wang X, Carlén M, Meletis K (2014) Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLoS One 9:e83879, and erratum (2014) 9:e91486.
15. Monteggia LM, Gideons E, Kavalali ET (2013) The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 73:1199-1203.
16. Autry AE, et al. (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95.
17. Maeng S, et al. (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352.
18. Nosyreva E, et al. (2013) Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci 33:6990-7002.
19. Zanos P, et al. (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481-486.
20. Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, Monteggia LM (2017) Effects of a ketamine metabolite on synaptic NMDAR function. Nature 546:E1-E3.
21. Preskorn S, et al.; GLYX-13 Clinical Study Group (2015) Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 21: 140-149.
22. Garcia LS, et al. (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32:140-144.
23. Drevets WC, Furey ML (2010) Replication of scopolamine's antidepressant efficacy in major depressive disorder: A randomized, placebo-controlled clinical trial. Biol Psychiatry 67:432-438.
24. Furey ML, Drevets WC (2006) Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 63: 1121-1129.
25. Navarria A, et al. (2015) Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol Dis 82:254-261.
26. Wohleb ES, et al. (2016) GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. J Clin Invest 126:2482-2494.
27. Voleti B, et al. (2013) Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 74:742-749.
28. Witkin JM, et al. (2014) M1 andM2muscarinic receptor subtypes regulate antidepressantlike effects of the rapidly acting antidepressant scopolamine. J Pharmacol Exp Ther 351: 448-456.
29. Martin AE, et al. (2017) Further evaluation of mechanisms associated with the antidepressant-like signature of scopolamine in mice. CNS Neurol Disord Drug Targets 16:492-500.
30. Hartvig P, et al. (1995) Central nervous system effects of subdissociative doses of (S)- ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 58:165-173.
31. Zhang XL, Sullivan JA, Moskal JR, Stanton PK (2008) A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 55:1238-1250.
32. Sanacora G (2016) What are we learning from early-phase clinical trials with glutamate targeting medications for the treatment of major depressive disorder. JAMA Psychiatry 73:651-652.
33. Ibrahim L, et al. (2012) A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 32:551-557.
34. Preskorn SH, et al. (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631-637.
35. Kamondi A, Acsády L, Wang XJ, Buzsáki G (1998) Theta oscillations in somata and dendrites of hippocampal pyramidal cells in vivo: Activity-dependent phaseprecession of action potentials. Hippocampus 8:244-261.
36. Buzsáki G (1986) Hippocampal sharp waves: Their origin and significance. Brain Res 398:242-252.
37. Burgdorf J, et al. (2013) GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38:729-742.
38. Jaso BA, et al. (2017) Therapeutic modulation of glutamate receptors in major depressive disorder. Curr Neuropharmacol 15:57-70.
39. Zhang K, et al. (2016) Essential roles of AMPA receptor GluA1 phosphorylation and presynaptic HCN channels in fast-acting antidepressant responses of ketamine. Sci Signal 9:ra123.
40. Izumi Y, Zorumski CF (2014) Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function. Neuropharmacology 86:273-281.
41. Povysheva NV, Johnson JW (2016) Effects of memantine on the excitation-inhibition balance in prefrontal cortex. Neurobiol Dis 96:75-83.
42. Parsons CG, Stöffler A, Danysz W (2007) Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system- Too little activation is bad, too much is even worse. Neuropharmacology 53:699-723.
43. Gideons ES, Kavalali ET, Monteggia LM (2014) Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA 111:8649-8654.
44. Mion G, Villevieille T (2013) Ketamine pharmacology: An update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 19:370-380.
45. Zarate CA, Jr, et al. (2006) A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163:153-155.
46. Smith EG, et al. (2013) Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 74:966-973.
47. MacQueen GM, et al. (2003) Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 100:1387-1392.
48. Kim CS, Brager DH, Johnston D (April 18, 2017) Perisomatic changes in h-channels regulate depressive behaviors following chronic unpredictable stress. Mol Psychiatry, 10.1038/mp.2017.28.
49. Magariños AM, McEwen BS (1995) Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: Involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 69:89-98.
50. Bredemann TM, McMahon LL (2014) 17β Estradiol increases resilience and improves hippocampal synaptic function in helpless ovariectomized rats. Psychoneuroendocrinology 42: 77-88.
51. Sousa N, Lukoyanov NV, Madeira MD, Almeida OF, Paula-Barbosa MM (2000) Reorganization of the morphology of hippocampal neurites and synapses after stressinduced damage correlates with behavioral improvement. Neuroscience 97:253-266.
52. Baxter LR, Jr, et al. (1989) Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 46:243-250.
53. Wagner G, et al. (2006) Cortical inefficiency in patients with unipolar depression: An event-related FMRI study with the Stroop task. Biol Psychiatry 59:958-965.
54. Matta JA, et al. (2013) Developmental origin dictates interneuron AMPA and NMDA receptor subunit composition and plasticity. Nat Neurosci 16:1032-1041.
55. Chamberland S, Topolnik L (2012) Inhibitory control of hippocampal inhibitory neurons. Front Neurosci 6:165.
56. Fischell J, Van Dyke AM, Kvarta MD, LeGates TA, Thompson SM (2015) Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors. Neuropsychopharmacology 40:2499-2509.
57. Zanos P, et al. (2017) A negative allosteric modulator for α5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice. eNeuro 4:ENEURO.0285- 16.2017.
58. Smith CC, McMahon LL (2006) Estradiol-induced increase in the magnitude of longterm potentiation is prevented by blocking NR2B-containing receptors. J Neurosci 26: 8517-8522.
59. Vedder LC, Smith CC, Flannigan AE, McMahon LL (2013) Estradiol-induced increase in novel object recognition requires hippocampal NR2B-containing NMDA receptors. Hippocampus 23:108-115.
60. Korn SJ, Giacchino JL, Chamberlin NL, Dingledine R (1987) Epileptiform burst activity induced by potassium in the hippocampus and its regulation by GABA-mediated inhibition. J Neurophysiol 57:325-340.
61. Roberson ED, et al. (2011) Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31:700-711.
62. Van der Kloot W (1991) The regulation of quantal size. Prog Neurobiol 36:93-130.